Q-omics provides the consensus-scored SOX2-OT profile across patient tissues and cancer cell-line models. SOX2-OT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SOX2-OT is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, SOX2-OT RNA expression shows 17,293 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRP, and THYM as cancer lineages where SOX2-OT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX2-OT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX2-OT survival associations across molecular data types. SOX2-OT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX2-OT RNA expression–survival associations across cancer types. High SOX2-OT expression shows unfavorable associations in UVM, but favorable associations in MESO, LUSC, SKCM, LUAD and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SOX2-OT RNA expression.
This table summarizes SOX2-OT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SOX2-OT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX2-OT shows lower tumor expression in KIRP, KIRC, THCA and KICH and higher tumor expression in HNSC and LUSC. The KIRP box plot shows higher SOX2-OT RNA expression in normal versus tumor tissue (log2 FC = −0.225, t-test p < 0.001).
This table shows molecular features associated with SOX2-OT in patient tissues and cancer cell lines. In patient samples, SOX2-OT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
